The iterative process of fluid biomarker development and validation in Alzheimer's disease.
作者信息
Bendlin Barbara B, Zetterberg Henrik
机构信息
Center for Health Disparities Research University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
出版信息
Alzheimers Dement (Amst). 2022 Jul 12;14(1):e12341. doi: 10.1002/dad2.12341. eCollection 2022.
Abstract
摘要
相似文献
1
The iterative process of fluid biomarker development and validation in Alzheimer's disease.阿尔茨海默病中流体生物标志物开发与验证的迭代过程。
Alzheimers Dement (Amst). 2022 Jul 12;14(1):e12341. doi: 10.1002/dad2.12341. eCollection 2022.
2
Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy.用于脑淀粉样血管病的脑脊液生物标志物。
Brain Commun. 2023 May 19;5(3):fcad159. doi: 10.1093/braincomms/fcad159. eCollection 2023.
3
A data-driven model of biomarker changes in sporadic Alzheimer's disease.散发性阿尔茨海默病生物标志物变化的数据驱动模型。
Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.
4
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.PTI-125 降低阿尔茨海默病患者的生物标志物。
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
5
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.突触前囊泡蛋白突触结合蛋白是阿尔茨海默病的一种新型生物标志物。
Alzheimers Res Ther. 2016 Oct 3;8(1):41. doi: 10.1186/s13195-016-0208-8.
6
Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.在存在阿尔茨海默病病理的情况下，不良血管风险与脑脊液生物标志物轴突损伤的证据有关。
J Alzheimers Dis. 2019;71(1):281-290. doi: 10.3233/JAD-190077.
7
Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.阿尔茨海默病和帕金森病中的脑脊液生物标志物——从病理生理学到临床实践
Mov Disord. 2016 Jun;31(6):836-47. doi: 10.1002/mds.26656. Epub 2016 May 4.
8
Personalized Computational Causal Modeling of the Alzheimer Disease Biomarker Cascade.阿尔茨海默病生物标志物级联的个性化计算因果建模
J Prev Alzheimers Dis. 2024;11(2):435-444. doi: 10.14283/jpad.2023.134.
9
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.患者脑脊液中的 tau 和淀粉样蛋白-β1-42。
Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.
10
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.阿尔茨海默病中脑脊液淀粉样蛋白-β与氟代硼吡咯（florbetapir）成像的独立信息
Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.
引用本文的文献
1
Comparing Symmetric Dimethylarginine and Amyloid-β42 as Predictors of Alzheimer's Disease Development.比较对称二甲基精氨酸和淀粉样蛋白β42作为阿尔茨海默病发展预测指标的研究
J Alzheimers Dis Rep. 2023 Dec 29;7(1):1427-1444. doi: 10.3233/ADR-230054. eCollection 2023.
2
Network Proximity Analysis Deciphers the Pharmacological Mechanism of Osthole against D-Galactose Induced Cognitive Disorder in Rats.网络邻近度分析揭示蛇床子素防治 D-半乳糖诱导大鼠认知障碍的药理机制。
Molecules. 2023 Dec 19;29(1):21. doi: 10.3390/molecules29010021.
3
Amyloid beta-correlated plasma metabolite dysregulation in Alzheimer's disease: an untargeted metabolism exploration using high-resolution mass spectrometry toward future clinical diagnosis.阿尔茨海默病中与β淀粉样蛋白相关的血浆代谢物失调：利用高分辨率质谱进行的非靶向代谢探索以用于未来临床诊断
Front Aging Neurosci. 2023 Jun 29;15:1189659. doi: 10.3389/fnagi.2023.1189659. eCollection 2023.
本文引用的文献
1
Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.肝脏和肾脏功能会影响神经病理学血浆生物标志物的浓度。
Alzheimers Dement (Amst). 2022 Jul 12;14(1):e12321. doi: 10.1002/dad2.12321. eCollection 2022.
2
Performance of plasma phosphorylated tau 181 and 217 in the community.社区人群中血浆磷酸化 tau181 和 tau217 的检测性能。
Nat Med. 2022 Jul;28(7):1398-1405. doi: 10.1038/s41591-022-01822-2. Epub 2022 May 26.
3
Alzheimer's disease drug development pipeline: 2022.2022年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2022 May 4;8(1):e12295. doi: 10.1002/trc2.12295. eCollection 2022.
4
Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.阿尔茨海默病神经成像计划（ADNI）中不同种族群体血浆和脑脊液生物标志物的比较。
Alzheimers Dement (Amst). 2022 May 1;14(1):e12315. doi: 10.1002/dad2.12315. eCollection 2022.
5
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.血浆 Aβ42/Aβ40、磷酸化 tau 和神经丝轻链对脑淀粉样变预测的种族影响。
Neurology. 2022 Jul 19;99(3):e245-e257. doi: 10.1212/WNL.0000000000200358. Epub 2022 Apr 21.
6
Alzheimer's disease - the journey of a healthy brain into organ failure.阿尔茨海默病——一个健康大脑走向器官衰竭的旅程。
Mol Neurodegener. 2022 Mar 5;17(1):18. doi: 10.1186/s13024-022-00523-1.
7
Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.认知正常成年人纵向阿尔茨海默病生物标志物的种族差异。
Alzheimers Dement. 2022 Dec;18(12):2570-2581. doi: 10.1002/alz.12608. Epub 2022 Feb 25.
8
Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.黑人和非西班牙裔白人群体中的阿尔茨海默病生物标志物：对证据的情境化回顾。
Alzheimers Dement. 2022 Aug;18(8):1545-1564. doi: 10.1002/alz.12511. Epub 2021 Dec 6.
9
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.用于阿尔茨海默病的血液生物标志物：迈向临床应用
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
10
Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.描述居住在社区的多民族队列中的血浆 NfL：来自 HABLE 研究的结果。
Alzheimers Dement. 2022 Feb;18(2):240-250. doi: 10.1002/alz.12404. Epub 2021 Jul 26.
Zotero 插件